普罗文奇的里程碑式批准，它对免疫学的意义以及“在本期”：疫苗与自身免疫之间的复杂关系。 - Suppr

Suppr

超能文献

The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.

作者信息

Bot Adrian

出版信息

Int Rev Immunol. 2010 Jun;29(3):235-8. doi: 10.3109/08830185.2010.490777.

DOI:10.3109/08830185.2010.490777

PMID:20521923

Abstract

摘要

相似文献

The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.

Int Rev Immunol. 2010 Jun;29(3):235-8. doi: 10.3109/08830185.2010.490777.

Concerns about Provenge simmer as CMS ponders coverage.

J Natl Cancer Inst. 2011 Feb 16;103(4):288-9. doi: 10.1093/jnci/djr041. Epub 2011 Feb 8.

Is Provenge Angst a symbol or symptom of the times?

Am J Manag Care. 2012 May;18(3 Spec No.):SP108-9.

The Provenge decision.

Nat Clin Pract Oncol. 2007 Jul;4(7):381. doi: 10.1038/ncponc0854.

A prostate cancer 'vaccine' under development.

Mayo Clin Health Lett. 2009 Dec;27(12):4.

Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.

Oncology (Williston Park). 2010 Sep;24(10):881-3.

Provenge: combating prostate cancer with a vengeance?

Expert Rev Vaccines. 2011 Aug;10(8):1113-4. doi: 10.1586/erv.11.85.

Listening to Provenge--what a costly cancer treatment says about future Medicare policy.

N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.

The regulator disapproves.

Nat Biotechnol. 2008 Jan;26(1):1. doi: 10.1038/nbt0108-1.

Fallout from flip-flops.

Nat Biotechnol. 2008 Jun;26(6):614-5. doi: 10.1038/nbt0608-614.

引用本文的文献

Therapeutic mRNA vaccine applications in oncology.

Mol Ther. 2025 Jun 4;33(6):2610-2618. doi: 10.1016/j.ymthe.2025.04.044. Epub 2025 May 6.

Cancer mRNA vaccines: clinical advances and future opportunities.

Nat Rev Clin Oncol. 2024 Jul;21(7):489-500. doi: 10.1038/s41571-024-00902-1. Epub 2024 May 17.

Fire in the Smoke: Battling Brain Tumors.

Cerebrum. 2018 May 1;2018. eCollection 2018 May-Jun.

Vaccine strategies for glioblastoma: progress and future directions.

Immunotherapy. 2013 Feb;5(2):155-67. doi: 10.2217/imt.12.155.

Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.

Front Oncol. 2012 Jun 28;2:66. doi: 10.3389/fonc.2012.00066. eCollection 2012.

Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?

Cancer Immunol Immunother. 2011 Aug;60(8):1181-93. doi: 10.1007/s00262-011-1065-8. Epub 2011 Jun 19.

NGcGM3 ganglioside: a privileged target for cancer vaccines.

Clin Dev Immunol. 2010;2010:814397. doi: 10.1155/2010/814397. Epub 2010 Oct 27.

Genome editing with engineered zinc finger nucleases.

Nat Rev Genet. 2010 Sep;11(9):636-46. doi: 10.1038/nrg2842.

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Mol Ther. 2010 Oct;18(10):1874-84. doi: 10.1038/mt.2010.161. Epub 2010 Jul 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.

Int Rev Immunol. 2010 Jun;29(3):235-8. doi: 10.3109/08830185.2010.490777.

Concerns about Provenge simmer as CMS ponders coverage.

J Natl Cancer Inst. 2011 Feb 16;103(4):288-9. doi: 10.1093/jnci/djr041. Epub 2011 Feb 8.

Is Provenge Angst a symbol or symptom of the times?

Am J Manag Care. 2012 May;18(3 Spec No.):SP108-9.

The Provenge decision.

Nat Clin Pract Oncol. 2007 Jul;4(7):381. doi: 10.1038/ncponc0854.

A prostate cancer 'vaccine' under development.

Mayo Clin Health Lett. 2009 Dec;27(12):4.

Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.

Oncology (Williston Park). 2010 Sep;24(10):881-3.

Provenge: combating prostate cancer with a vengeance?

Expert Rev Vaccines. 2011 Aug;10(8):1113-4. doi: 10.1586/erv.11.85.

Listening to Provenge--what a costly cancer treatment says about future Medicare policy.

N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.

The regulator disapproves.

Nat Biotechnol. 2008 Jan;26(1):1. doi: 10.1038/nbt0108-1.

Fallout from flip-flops.

Nat Biotechnol. 2008 Jun;26(6):614-5. doi: 10.1038/nbt0608-614.

引用本文的文献

Therapeutic mRNA vaccine applications in oncology.

Mol Ther. 2025 Jun 4;33(6):2610-2618. doi: 10.1016/j.ymthe.2025.04.044. Epub 2025 May 6.

Cancer mRNA vaccines: clinical advances and future opportunities.

Nat Rev Clin Oncol. 2024 Jul;21(7):489-500. doi: 10.1038/s41571-024-00902-1. Epub 2024 May 17.

Fire in the Smoke: Battling Brain Tumors.

Cerebrum. 2018 May 1;2018. eCollection 2018 May-Jun.

Vaccine strategies for glioblastoma: progress and future directions.

Immunotherapy. 2013 Feb;5(2):155-67. doi: 10.2217/imt.12.155.

Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.

Front Oncol. 2012 Jun 28;2:66. doi: 10.3389/fonc.2012.00066. eCollection 2012.

Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?

Cancer Immunol Immunother. 2011 Aug;60(8):1181-93. doi: 10.1007/s00262-011-1065-8. Epub 2011 Jun 19.

NGcGM3 ganglioside: a privileged target for cancer vaccines.

Clin Dev Immunol. 2010;2010:814397. doi: 10.1155/2010/814397. Epub 2010 Oct 27.

Genome editing with engineered zinc finger nucleases.

Nat Rev Genet. 2010 Sep;11(9):636-46. doi: 10.1038/nrg2842.

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Mol Ther. 2010 Oct;18(10):1874-84. doi: 10.1038/mt.2010.161. Epub 2010 Jul 27.